JOURNEY MEDICAL CORPORATION - COMMON STOCK

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

02 янв 2024 15:05:30 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 дек 2023 07:00:51 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 ноя 2023 15:01:18 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 окт 2023 07:30:12 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 окт 2023 07:30:59 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 сен 2023 07:00:04 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 авг 2023 15:01:33 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 авг 2023 15:01:42 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 июл 2023 07:30:00 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 июл 2023 07:30:20 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 июн 2023 07:30:59 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 май 2023 15:01:31 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 май 2023 15:01:27 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 май 2023 15:01:01 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 май 2023 08:00:26 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

29 мар 2023 15:01:11 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

22 мар 2023 08:00:54 Источник Nasdaq GlobeNewswire

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

16 мар 2023 07:30:32 Источник Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

07 мар 2023 07:30:31 Источник Nasdaq GlobeNewswire